Erlotinib
Information
- Drug Name
- Erlotinib
- Description
- Entry(CIViC)
- 112
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A 39-year-old man presented was observed to have l... | ALK | ALK EML4-ALK | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Expression of EGFRvIII and PTEN was evaluated in 2... | EGFR | EGFR VIII EGFR VIII | Sensitivity | true | CIViC Evidence | detail |
| Expression of EGFRvIII and PTEN was evaluated in 2... | PTEN | PTEN EXPRESSION PTEN EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| In a study of 448 metastatic colorectal cancer pat... | KRAS |
KRAS p.Gly12Cys (p.G12C) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Cys (p.G12C) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a retrospective study of 136 pancreatic cancer ... | KRAS | KRAS EXON 2 MUTATION KRAS EXON 2 MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 155 patients with lung adenocarcinomas underwent r... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 155 patients with lung adenocarcinomas underwent r... | MET |
MET AMPLIFICATION ( ENST00000318493.11 ) MET AMPLIFICATION ( ENST00000318493.11 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 155 patients with lung adenocarcinomas underwent r... | ERBB2 |
ERBB2 AMPLIFICATION ( ENST00000269571.10 ) ERBB2 AMPLIFICATION ( ENST00000269571.10 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| A patient with metastatic lung adenocarcinoma was ... | EGFR |
EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 ) EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| 48 tumor samples from 41 patients with EGFR mutant... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| 48 tumor samples from 41 patients with EGFR mutant... | PIK3CA |
PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) PIK3CA p.Glu545Lys (p.E545K) ( ENST00000263967.4, ENST00000643187.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| An ERRFI1 (E384X) was detected in a patient with m... | ERRFI1 |
ERRFI1 p.Glu384Ter (p.E384*) ( ENST00000377482.10, ENST00000474874.5, ENST00000467067.1 ) ERRFI1 p.Glu384Ter (p.E384*) ( ENST00000377482.10, ENST00000467067.1, ENST00000474874.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| This small clinical (n=56) study suggests that pat... | EGFR |
EGFR p.Gly719Ser (p.G719S) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 ) EGFR p.Gly719Ser (p.G719S) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| D761Y as a secondary mutation was reported to be a... | EGFR |
EGFR p.Asp761Tyr (p.D761Y) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Asp761Tyr (p.D761Y) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a meta-analysis of 7 clinical trials of erlotin... | EGFR | EGFR G719 EGFR G719 | Sensitivity | true | CIViC Evidence | detail |
| Efficacy of erlotinib treatment was evaluated by m... | EGFR | EGFR S720 EGFR S720 | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a meta-analysis of 7 clinical trials evaluating... | EGFR |
EGFR p.Lys757Arg (p.K757R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Lys757Arg (p.K757R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a meta-analysis of 7 clinical trials evaluating... | EGFR |
EGFR p.Glu746Gly (p.E746G) ( ENST00000455089.5, ENST00000275493.7, ENST00000450046.2 ) EGFR p.Glu746Gly (p.E746G) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Although EGFR exon 20 insertions may confer reduce... | EGFR |
EGFR p.Ala767_Val769dup (p.A767_V769dup) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Ala767_Val769dup (p.A767_V769dup) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| The disease control rate of patients with GNAS1 T3... | GNAS |
GNAS p.Leu131= (p.L131=) ( ENST00000306090.12, ENST00000306120.4, ENST00000313949.11, ENST00000349036.9, ENST00000371075.7, ENST00000371098.6, ENST00000371100.9, ENST00000371102.8, ENST00000419558.7, ENST00000423897.7, ENST00000453292.7, ENST00000462499.6, ENST00000467227.6, ENST00000472183.6, ENST00000482112.6, ENST00000491348.5, ENST00000493744.5, ENST00000657090.1, ENST00000663479.2, ENST00000676826.2 ) GNAS p.Leu131= (p.L131=) ( ENST00000306090.12, ENST00000306120.4, ENST00000313949.11, ENST00000349036.9, ENST00000371075.7, ENST00000371098.6, ENST00000371100.9, ENST00000371102.8, ENST00000419558.7, ENST00000423897.7, ENST00000453292.7, ENST00000462499.6, ENST00000467227.6, ENST00000472183.6, ENST00000482112.6, ENST00000491348.5, ENST00000493744.5, ENST00000657090.1, ENST00000663479.2, ENST00000676826.2 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a retrospective study, 166 non-small cell lung ... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| There is no statistical difference in progression ... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a retrospective study, 166 non-small cell lung ... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| The T790M mutation in EGFR has been shown to confe... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a retrospective study, 166 non-small cell lung ... | KRAS | KRAS MUTATION KRAS MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| KRAS mutations (N=29 G12, N=1 G13) were the primar... | KRAS |
KRAS p.Gly12Ala (p.G12A) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000686969.1, ENST00000688940.1, ENST00000692768.1, ENST00000693229.1 ) KRAS p.Gly12Ala (p.G12A) ( ENST00000256078.10, ENST00000311936.8, ENST00000556131.2, ENST00000557334.6, ENST00000685328.1, ENST00000692768.1, ENST00000693229.1, ENST00000686969.1, ENST00000688940.1 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| EGFR exons 18-24 were analyzed in 7 patients who h... | EGFR |
EGFR p.Glu746_Ala750del (p.E746_A750del) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Glu746_Ala750del (p.E746_A750del) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a phase II trial for bronchioloalveolar carcino... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a patient expressing a DDR2 S768R mutation, tre... | DDR2 |
DDR2 p.Ser768Arg (p.S768R) ( ENST00000367921.8, ENST00000367922.7, ENST00000446985.6 ) DDR2 p.Ser768Arg (p.S768R) ( ENST00000367921.8, ENST00000446985.6, ENST00000367922.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| In NSCLC patients treated with EGFR tyrosine kinas... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an NSCLC patient initially with L858R mutation,... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| S768I mutations in exon 20 of the EGFR gene are ra... | EGFR |
EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 ) EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | false | CIViC Evidence | detail |
| On May 14, 2013, the U.S. Food and Drug Administra... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| On May 14, 2013, the U.S. Food and Drug Administra... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| In 60 patients with NSCLC, Exon 2 KRAS mutations w... | KRAS | KRAS G12/G13 KRAS G12/G13 | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| The phase 3 (EURTAC) study consisted of of 173 non... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a phase II trial for Bronchioloalveolar carcino... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Experimental - EGFR T790M mutation has been associ... | EGFR |
EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Thr790Met (p.T790M) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
N/A | true | CIViC Evidence | detail |
| EGFR L858R was expressed in Ba/F3 cells which do n... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In the placebo-controlled Phase III study SATURN, ... | KRAS | KRAS MUTATION KRAS MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| NSCLC patients with exon 19 deletions in EGFR had ... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR R108K EGFR R108K | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR T263P EGFR T263P | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR |
EGFR p.Ala289Val (p.A289V) ( ENST00000275493.7, ENST00000342916.7, ENST00000344576.7, ENST00000420316.6, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Ala289Val (p.A289V) ( ENST00000275493.7, ENST00000342916.7, ENST00000420316.6, ENST00000344576.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| EGFR G719 mutations have been associated with incr... | EGFR | EGFR G719 EGFR G719 | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR |
EGFR p.Gly719Ser (p.G719S) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 ) EGFR p.Gly719Ser (p.G719S) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR V742A EGFR V742A | Sensitivity | true | CIViC Evidence | detail |
| In the placebo-controlled Phase III study SATURN, ... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a study, 2 participants with stage IV lung aden... | EGFR | EGFR G719D EGFR G719D | Sensitivity | true | CIViC Evidence | detail |
| In a study, 2 participants with stage IV adenocarc... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Sensitivity | false | CIViC Evidence | detail |
| In a study, 1 participant with stage IV squamous c... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Sensitivity | false | CIViC Evidence | detail |
| In a study, 1 participant with stage IV lung adeno... | EGFR |
EGFR p.Asn826Tyr (p.N826Y) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Asn826Tyr (p.N826Y) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | false | CIViC Evidence | detail |
| In a study of 1261 non-small cell lung cancer pati... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| MCF-7 cells were transduced with YFP tagged EGFR w... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR L747_P753delinsS EGFR L747_P753delinsS | Sensitivity | true | CIViC Evidence | detail |
| In stage IV lung adenocarcinoma patients (n=2) har... | EGFR |
EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 ) EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR |
EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000455089.5, ENST00000450046.2 ) EGFR p.Ser768Ile (p.S768I) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR |
EGFR p.Ser768_Asp770dup (p.S768_D770dup) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Ser768_Asp770dup (p.S768_D770dup) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a COS-7 cell line expressing... | EGFR |
EGFR p.Arg831His (p.R831H) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Arg831His (p.R831H) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study using NCI-H1666 cells (wildty... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a MCF-7 cell line expressing... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, Ba/F3 and NCI-H3255 cell lin... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, CHO and NCI-H3255 cells expr... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a retrospective study of 46 Caucasian, advanced... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, Ba/F3 cell line expressing E... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study using NCI-H3255 cells (EGFR L... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
N/A | false | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| EGFR L861 mutations have been associated with incr... | EGFR | EGFR L861Q EGFR L861Q | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR L861Q EGFR L861Q | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a COS-7 cell line expressing... | EGFR | EGFR E868G EGFR E868G | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR R776C EGFR R776C | Sensitivity | true | CIViC Evidence | detail |
| In a lung adenocarcinoma patient harboring EGFR H7... | EGFR |
EGFR p.Asn771_His773dup (p.N771_H773dup) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Asn771_His773dup (p.N771_H773dup) ( ENST00000450046.2, ENST00000455089.5, ENST00000275493.7 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 19 non-small cell lung carcinoma pat... | EGFR |
EGFR p.Asp770_Asn771insGlyLeu (p.D770_N771insGL) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Asp770_Asn771insGlyLeu (p.D770_N771insGL) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR |
EGFR p.Ala864Thr (p.A864T) ( ENST00000455089.5, ENST00000275493.7, ENST00000450046.2 ) EGFR p.Ala864Thr (p.A864T) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR N826S EGFR N826S | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, Ba/F3 and BID007 cell lines ... | EGFR |
EGFR p.Ala763_Tyr764insPheGlnGluAla (p.A763_Y764insFQEA) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Ala763_Tyr764insPheGlnGluAla (p.A763_Y764insFQEA) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR VIII EGFR VIII | Sensitivity | true | CIViC Evidence | detail |
| In a lung adenocarcinoma patient harboring EGFR D7... | EGFR |
EGFR p.Asp770_Asn771insGlyThr (p.D770_N771insGT) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Asp770_Asn771insGlyThr (p.D770_N771insGT) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In stage IV lung adenocarcinoma patients (n=2) har... | EGFR | EGFR EXON 20 INSERTION EGFR EXON 20 INSERTION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a COS-7 cell line expressing... | EGFR | EGFR W731L EGFR W731L | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a COS-7 cell line expressing... | EGFR | EGFR E734Q EGFR E734Q | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a COS-7 cell line expressing... | EGFR | EGFR T785A EGFR T785A | Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a COS-7 cell line expressing... | EGFR |
EGFR p.Cys797Tyr (p.C797Y) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Cys797Tyr (p.C797Y) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a COS-7 cell line expressing... | EGFR | EGFR Y801H EGFR Y801H | Sensitivity | true | CIViC Evidence | detail |
| In a study of 19 non-small cell lung carcinoma pat... | EGFR |
EGFR p.Ala767_Val769dup (p.A767_V769dup) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Ala767_Val769dup (p.A767_V769dup) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| EGFR exons 18-24 were analyzed in 7 patients who h... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Sensitivity | true | CIViC Evidence | detail |
| In a cohort of NSCLC patients treated with tyrosin... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a study of 1261 non-small cell lung cancer pati... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| In a cohort of NSCLC patients tested for mutation ... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | false | CIViC Evidence | detail |
| In a stage IV lung adenocarcinoma patient harborin... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In an in vitro study, a Ba/F3 cell line expressing... | EGFR | EGFR E746_T751>I EGFR E746_T751>I | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a study of 19 non-small cell lung carcinoma pat... | EGFR | EGFR MUTATION EGFR MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a non-small cell lung cancer patient harboring ... | EGFR | EGFR MUTATION EGFR MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a lung adenocarcinoma patient harboring EGFR P7... | EGFR | EGFR MUTATION EGFR MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Non-small cell cancer patients from two studies [T... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| 38 KRAS wild-type patients were randomized to erlo... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | false | CIViC Evidence | detail |
| 222 EGFR-wt patients with advanced NSCLC were rand... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | false | CIViC Evidence | detail |
| The result of the analysis found that EGFR gene co... | EGFR |
EGFR COPY NUMBER VARIATION ( ENST00000275493.7 ) EGFR COPY NUMBER VARIATION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| Among TKI-treated patients, increased EGFR gene co... | EGFR |
EGFR COPY NUMBER VARIATION ( ENST00000275493.7 ) EGFR COPY NUMBER VARIATION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| In a large retrospective study, EGFR exons 18-21 w... | EGFR |
EGFR p.Gly719Ala (p.G719A) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Gly719Ala (p.G719A) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | false | CIViC Evidence | detail |
| In a large retrospective study, EGFR exons 18-21 w... | EGFR | EGFR R705K EGFR R705K | Sensitivity | false | CIViC Evidence | detail |
| In this open-label, randomised, phase 3 trial at 2... | EGFR | EGFR MUTATION EGFR MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Case report of a patient with stage IVA HNSCC with... | MAPK1 |
MAPK1 p.Glu322Lys (p.E322K) ( ENST00000215832.11, ENST00000398822.7, ENST00000544786.1 ) MAPK1 p.Glu322Lys (p.E322K) ( ENST00000398822.7, ENST00000215832.11, ENST00000544786.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| A randomized phase 3 trial involving 173 NSCLC pat... | EGFR |
EGFR EXON 19 DELETION ( ENST00000275493.7 ) EGFR EXON 19 DELETION ( ENST00000275493.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| A randomized phase 3 trial (NCT00446225) involving... | EGFR |
EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) EGFR p.Leu858Arg (p.L858R) ( ENST00000275493.7, ENST00000450046.2, ENST00000455089.5 ) |
Sensitivity | true | CIViC Evidence | detail |
| Overexpression of EGFR exon 18 (Affymetrix Human E... | EGFR |
EGFR EXON 18 OVEREXPRESSION ( ENST00000344576.7 ) EGFR EXON 18 OVEREXPRESSION ( ENST00000344576.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| KRAS exon 2 was mutated in 121 of 173 (70%) patien... | KRAS | KRAS EXON 2 MUTATION KRAS EXON 2 MUTATION | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| While EGFR mutation is a strong predictive factor ... | EGFR | EGFR Y1092 PHOSPHORYLATION EGFR Y1092 PHOSPHORYLATION | Sensitivity | true | CIViC Evidence | detail |
| In 290 patients with advanced NSCLC, 177 of which ... | EGFR |
EGFR AMPLIFICATION ( ENST00000275493.7 ) EGFR AMPLIFICATION ( ENST00000275493.7 ) |
Sensitivity | false | CIViC Evidence | detail |
| Erlotinib: small molecule inhibitor of EGFR. While... | EGFR | EGFR EXPRESSION | Sensitivity | true | MMMP | detail |
| Erlotinib: small molecule inhibitor of EGFR. In vi... | VEGFA | VEGFA UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03498521 | Active, not recruiting | Phase 2 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | July 10, 2018 | June 9, 2024 |
| NCT02099058 | Active, not recruiting | Phase 1 | A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | January 15, 2014 | November 16, 2024 |
| NCT01897480 | Active, not recruiting | Phase 2 | A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations | August 28, 2013 | December 31, 2024 |
| NCT02633189 | Active, not recruiting | Phase 3 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer | April 2016 | July 2024 |
| NCT01306045 | Active, not recruiting | Phase 2 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | February 8, 2011 | December 31, 2024 |
| NCT02411448 | Active, not recruiting | Phase 3 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) | May 6, 2015 | December 16, 2024 |
| NCT01130519 | Active, not recruiting | Phase 2 | A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer | May 6, 2010 | December 1, 2024 |
| NCT00600496 | Active, not recruiting | Phase 1 | A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) | December 14, 2007 | December 31, 2024 |
| NCT04591431 | Active, not recruiting | Phase 2 | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | October 7, 2020 | June 2025 |
| NCT02152631 | Active, not recruiting | Phase 3 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer | October 3, 2014 | December 31, 2024 |
| NCT00193258 | Completed | Phase 1/Phase 2 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | June 2004 | August 2011 |
| NCT00193622 | Completed | Phase 2 | Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site | April 2004 | January 2009 |
| NCT00230126 | Completed | Phase 2 | OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer | October 2005 | July 2013 |
| NCT00242502 | Completed | Phase 2 | Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery | October 2005 | October 2011 |
| NCT00254384 | Completed | Phase 1 | Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery | October 5, 2005 | May 21, 2024 |
| NCT00265317 | Completed | Phase 2 | A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone | June 2006 | January 2012 |
| NCT00278148 | Completed | Phase 1/Phase 2 | Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer | October 2005 | February 2011 |
| NCT00287222 | Completed | Phase 2 | Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma | February 2006 | September 2010 |
| NCT00300586 | Completed | Phase 3 | IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer | June 2006 | March 2011 |
| NCT00301418 | Completed | Phase 1/Phase 2 | Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma | March 2006 | May 2014 |
| NCT00307736 | Completed | Phase 1/Phase 2 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | May 2006 | July 2011 |
| NCT00321815 | Completed | Phase 2 | Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer | August 2006 | June 2010 |
| NCT00349219 | Completed | Phase 3 | TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer | December 2006 | June 2012 |
| NCT00360360 | Completed | Phase 2 | Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site | July 2006 | March 2009 |
| NCT00364351 | Completed | Phase 3 | Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | August 2006 | November 2016 |
| NCT00366457 | Completed | Phase 2 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | August 2006 | July 2011 |
| NCT00367601 | Completed | Phase 2 | Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer | August 2006 | December 2008 |
| NCT00369512 | Completed | Phase 2 | A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma | August 2006 | September 2012 |
| NCT00369889 | Completed | Phase 2 | A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer | August 2006 | September 2007 |
| NCT00370383 | Completed | Phase 2 | A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC) | July 2006 | March 2009 |
| NCT00373425 | Completed | Phase 3 | A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors | September 2006 | June 2014 |
| NCT00380029 | Completed | Phase 2 | Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer | May 2006 | June 2014 |
| NCT00384826 | Completed | Phase 2 | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | September 2006 | February 2014 |
| NCT00391248 | Completed | Phase 2 | Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL) | November 2006 | December 2012 |
| NCT00392704 | Completed | Phase 2 | Treatment of Head & Neck Cancer With Chemotherapy and Radiation | December 2006 | May 2012 |
| NCT00393068 | Completed | Phase 2 | Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer | February 2007 | August 2011 |
| NCT00400374 | Completed | Phase 1 | Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2 | August 2007 | November 2016 |
| NCT00402779 | Completed | Phase 3 | Erlotinib Prevention of Oral Cancer (EPOC) | November 3, 2006 | June 4, 2018 |
| NCT00405405 | Completed | Phase 1 | Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer | December 2006 | June 2010 |
| NCT00408499 | Completed | Phase 1/Phase 2 | Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer | August 2006 | January 2013 |
| NCT00410059 | Completed | Phase 2 | BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC | November 2006 | July 2016 |
| NCT00411632 | Completed | Phase 2 | BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | November 29, 2006 | February 23, 2018 |
| NCT00418704 | Completed | Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC) | May 2006 | June 2009 | |
| NCT00446225 | Completed | Phase 3 | Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR | February 2007 | December 2012 |
| NCT00447057 | Completed | Phase 2 | Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) | March 2007 | June 2011 |
| NCT01900652 | Completed | Phase 2 | A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants | August 2013 | March 2016 |
| NCT00112736 | Completed | Phase 1/Phase 2 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | April 2005 | April 2014 |
| NCT00113347 | Completed | Phase 1 | Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) | April 2005 | April 2011 |
| NCT00116506 | Completed | Phase 2 | Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer | January 2005 | July 2007 |
| NCT00126581 | Completed | Phase 2 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | August 15, 2005 | November 28, 2017 |
| NCT00130520 | Completed | Phase 2 | Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer | June 2005 | May 2010 |
| NCT00137826 | Completed | Phase 2 | Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | February 2004 | July 2009 |
| NCT00137839 | Completed | Phase 2 | Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | November 2004 | July 2019 |
| NCT00140556 | Completed | Early Phase 1 | Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer | August 2005 | April 2010 |
| NCT00147537 | Completed | Phase 1/Phase 2 | Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer | February 2005 | August 2011 |
| NCT00609804 | Completed | Phase 2 | Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib | March 2008 | November 2014 |
| NCT00611468 | Completed | Phase 1 | Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors | June 2006 | August 2009 |
| NCT00614653 | Completed | Phase 1 | Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer | January 2008 | July 2016 |
| NCT00615758 | Completed | Phase 2 | Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV | October 2006 | November 2009 |
| NCT00619424 | Completed | Phase 1 | A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors | November 15, 2007 | September 4, 2009 |
| NCT00642473 | Completed | Phase 2 | A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash | February 2008 | March 2009 |
| NCT00654420 | Completed | Phase 2 | A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007) | March 19, 2008 | February 13, 2012 |
| NCT00674973 | Completed | Phase 2 | A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer | June 2008 | March 2015 |
| NCT00692640 | Completed | Phase 1 | Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors | May 2008 | November 2011 |
| NCT00696696 | Completed | Phase 2 | Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer | September 2007 | June 2013 |
| NCT00701558 | Completed | Phase 2 | A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer | August 2008 | December 2010 |
| NCT00702182 | Completed | Phase 1 | Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer | April 2008 | October 2012 |
| NCT00708448 | Completed | Phase 1 | Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients | March 28, 2008 | August 12, 2010 |
| NCT00709826 | Completed | Phase 2 | APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer | August 2008 | May 2011 |
| NCT00732810 | Completed | Phase 2 | SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) | July 2008 | June 2011 |
| NCT00737243 | Completed | Phase 2 | Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site | August 2008 | December 2012 |
| NCT00738751 | Completed | Phase 1 | Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers | November 2008 | February 2015 |
| NCT00739453 | Completed | Phase 1 | A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) | October 23, 2008 | March 3, 2012 |
| NCT00743938 | Completed | Phase 2 | A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC | March 2009 | June 2012 |
| NCT00759928 | Completed | Phase 1 | PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors | October 2008 | June 2014 |
| NCT00761345 | Completed | Phase 1 | Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer | September 2008 | February 2015 |
| NCT00769067 | Completed | Phase 2 | A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen | November 2008 | August 2014 |
| NCT00769483 | Completed | Phase 1/Phase 2 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | November 13, 2008 | September 1, 2020 |
| NCT00770263 | Completed | Phase 1 | Erlotinib and Temsirolimus for Solid Tumors | May 2009 | September 2014 |
| NCT00777309 | Completed | Phase 2 | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | September 2008 | August 2011 |
| NCT00777699 | Completed | Phase 1 | Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors | August 2008 | February 2011 |
| NCT00779389 | Completed | Phase 1 | Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family | January 2009 | February 2014 |
| NCT00810719 | Completed | Phase 2 | Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer | April 2009 | December 2013 |
| NCT00826449 | Completed | Phase 1/Phase 2 | Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC) | February 2009 | June 2014 |
| NCT00834678 | Completed | Phase 1/Phase 2 | Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer | April 2009 | September 2014 |
| NCT00835471 | Completed | Phase 2 | 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) | March 2009 | June 2019 |
| NCT00840125 | Completed | Phase 2 | Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment | February 2009 | August 2011 |
| NCT00848718 | Completed | Phase 1 | A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) | March 17, 2009 | May 17, 2012 |
| NCT00855894 | Completed | Phase 2 | A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer | March 2009 | March 2012 |
| NCT00874419 | Completed | Phase 3 | Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation | August 2008 | July 2012 |
| NCT00883480 | Completed | N/A | Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma | June 2005 | November 2008 |
| NCT00884845 | Completed | Phase 1 | Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors | January 2009 | June 2011 |
| NCT00895362 | Completed | Phase 1 | Erlotinib in Combination With Cetuximab | April 2009 | |
| NCT00942734 | Completed | Phase 2 | Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma | July 2009 | November 2014 |
| NCT00949910 | Completed | Phase 4 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | November 2004 | April 2009 |
| NCT00965731 | Completed | Phase 1 | Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer | January 2010 | January 2014 |
| NCT00977548 | Completed | Phase 2 | Erlotinib Study for Myelodysplastic Syndrome (MDS) | September 2009 | June 2012 |
| NCT00983307 | Completed | Phase 2 | A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer | August 27, 2009 | December 2012 |
| NCT00994123 | Completed | Phase 1/Phase 2 | A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer | February 2010 | June 2015 |
| NCT00997334 | Completed | Phase 2 | Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC | February 2010 | January 2017 |
| NCT00998036 | Completed | Phase 1 | Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | September 2009 | October 2012 |
| NCT01009073 | Completed | Phase 1 | A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects | October 2009 | June 2013 |
| NCT01010945 | Completed | Phase 1 | Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer | February 3, 2010 | January 25, 2012 |
| NCT01024413 | Completed | Phase 3 | Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations | July 2009 | June 2015 |
| NCT01027598 | Completed | Phase 2 | Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | January 2010 | June 2014 |
| NCT01085838 | Completed | Phase 1/Phase 2 | Erlotinib in Higher Risk Myelodysplastic Syndrome | July 2010 | March 2014 |
| NCT01101334 | Completed | Phase 2 | Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer | March 2010 | April 2013 |
| NCT01116336 | Completed | Phase 1 | Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck | March 2010 | May 2018 |
| NCT01130753 | Completed | Phase 2 | Efficacy of Erlotinib in Neoadjuvant Setting in Patients With Stage IIIA, N2-positive Non-Small Cell Lung Cancer | January 2007 | December 2012 |
| NCT01153984 | Completed | Phase 2 | A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations | June 2011 | July 2015 |
| NCT01161173 | Completed | An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer | April 2008 | August 2012 | |
| NCT01174043 | Completed | Phase 2 | Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia | July 2010 | March 2012 |
| NCT01180959 | Completed | Phase 2 | Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy | April 14, 2011 | May 19, 2021 |
| NCT01186861 | Completed | Phase 2 | Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | March 4, 2011 | March 11, 2015 |
| NCT01187901 | Completed | Phase 2 | A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients | April 2010 | July 2014 |
| NCT01192165 | Completed | Phase 1 | Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | September 14, 2010 | October 7, 2013 |
| NCT01197170 | Completed | Phase 1 | Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | September 7, 2010 | January 13, 2021 |
| NCT01198028 | Completed | Phase 2 | Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma | March 10, 2011 | May 1, 2019 |
| NCT01199068 | Completed | Phase 1 | CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | June 2010 | December 2011 |
| NCT01210911 | Completed | Phase 2 | Metformin Combined With Chemotherapy for Pancreatic Cancer | August 2010 | April 2014 |
| NCT01211483 | Completed | Phase 1/Phase 2 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | September 2010 | November 23, 2013 |
| NCT01217619 | Completed | Phase 2 | Erlotinib as Neoadjuvant Treatment in Patients With Stage ⅢA N2 NSCLC With Activating EGFR Mutation. | March 2, 2011 | October 30, 2016 |
| NCT01221077 | Completed | Phase 2 | Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene | April 8, 2011 | September 1, 2014 |
| NCT01229150 | Completed | Phase 2 | Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... | October 26, 2010 | November 21, 2015 |
| NCT01230710 | Completed | Phase 4 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression | March 2011 | September 2013 |
| NCT01248247 | Completed | Phase 2 | BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer | June 2, 2011 | November 30, 2020 |
| NCT01257594 | Completed | Phase 1 | EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas | January 7, 2011 | December 31, 2018 |
| NCT01260181 | Completed | Phase 2 | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | March 31, 2011 | September 29, 2017 |
| NCT01310036 | Completed | Phase 2 | A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations | April 30, 2011 | December 30, 2016 |
| NCT01328951 | Completed | Phase 3 | A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy | September 2011 | January 2016 |
| NCT01342965 | Completed | Phase 3 | A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations | March 2011 | April 2014 |
| NCT01351415 | Completed | Phase 3 | A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | June 25, 2011 | June 25, 2016 |
| NCT01378962 | Completed | Phase 2 | A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER) | March 31, 2011 | January 31, 2017 |
| NCT01402089 | Completed | Phase 4 | Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients | January 2012 | November 2015 |
| NCT01454102 | Completed | Phase 1 | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | December 16, 2011 | July 23, 2021 |
| NCT01456325 | Completed | Phase 3 | A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung) | January 2012 | January 2016 |
| NCT01472016 | Completed | Phase 1 | Study of ABT-700 in Subjects With Advanced Solid Tumors | October 6, 2011 | April 27, 2017 |
| NCT01482377 | Completed | Phase 1 | A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin | December 2011 | February 2016 |
| NCT01505413 | Completed | Phase 2 | Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer | January 2011 | March 2014 |
| NCT01515137 | Completed | Phase 1 | Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma | November 2005 | September 2014 |
| NCT01523587 | Completed | Phase 3 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | March 5, 2012 | December 27, 2017 |
| NCT01532011 | Completed | Phase 1 | Erlotinib in Combination With Pralatrexate in Advanced Malignancies | March 2012 | June 2016 |
| NCT01532089 | Completed | Phase 2 | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | March 16, 2012 | August 18, 2020 |
| NCT01556191 | Completed | Phase 2 | Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR | May 15, 2012 | June 17, 2020 |
| NCT01562028 | Completed | Phase 2 | BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) | June 2012 | October 31, 2018 |
| NCT01565538 | Completed | Phase 2 | Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma | December 2008 | May 2013 |
| NCT01573702 | Completed | Phase 2 | Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR) | December 11, 2012 | March 15, 2019 |
| NCT01578668 | Completed | Phase 2 | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases | January 2012 | January 2015 |
| NCT01594398 | Completed | Phase 1 | Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer | May 2012 | May 2014 |
| NCT01602289 | Completed | Phase 1 | A Study of LY2875358 in Japanese Participants With Advanced Cancer | June 2012 | August 2014 |
| NCT01636908 | Completed | N/A | Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | August 2011 | December 1, 2019 |
| NCT01650506 | Completed | Phase 1 | Study of Erlotinib and Metformin in Triple Negative Breast Cancer | July 2012 | June 2016 |
| NCT01652469 | Completed | Phase 3 | Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. | August 2012 | December 2015 |
| NCT01664533 | Completed | An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy | September 2011 | August 2013 | |
| NCT01667562 | Completed | Phase 3 | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | January 20, 2012 | September 7, 2017 |
| NCT01727869 | Completed | Phase 1 | Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer | October 2012 | January 2015 |
| NCT01782690 | Completed | An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer | March 31, 2012 | February 28, 2015 | |
| NCT01801111 | Completed | Phase 1/Phase 2 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | June 20, 2013 | October 27, 2017 |
| NCT01859026 | Completed | Phase 1 | A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | December 30, 2013 | August 22, 2019 |
| NCT01887795 | Completed | Phase 3 | Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study | August 2013 | August 2016 |
| NCT01887886 | Completed | Phase 3 | A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation | December 2013 | February 2015 |
| NCT00059787 | Completed | Phase 2 | Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma | April 2003 | May 2010 |
| NCT01967095 | Completed | Phase 1 | Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer | October 15, 2013 | November 8, 2018 |
| NCT01998126 | Completed | Phase 1 | Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer | December 2, 2013 | March 29, 2018 |
| NCT02000531 | Completed | Phase 4 | Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population | January 2014 | December 2014 |
| NCT02013219 | Completed | Phase 1 | A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) | April 3, 2014 | February 5, 2020 |
| NCT02039674 | Completed | Phase 1/Phase 2 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | February 21, 2014 | October 18, 2021 |
| NCT02057380 | Completed | Phase 2 | A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | April 16, 2014 | December 21, 2016 |
| NCT02064491 | Completed | Phase 2 | Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC | February 2014 | May 31, 2017 |
| NCT02091141 | Completed | Phase 2 | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | April 14, 2014 | May 24, 2023 |
| NCT02154737 | Completed | Phase 1 | Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer | July 2013 | September 3, 2020 |
| NCT02155465 | Completed | Phase 1/Phase 2 | Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib | June 2014 | October 2017 |
| NCT02273362 | Completed | Phase 1/Phase 2 | Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver | November 24, 2014 | March 10, 2022 |
| NCT02352948 | Completed | Phase 3 | A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer | January 13, 2015 | August 30, 2023 |
| NCT02424617 | Completed | Phase 1/Phase 2 | A Study of BGB324(Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer | March 2015 | August 25, 2021 |
| NCT02450591 | Completed | N/A | Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations | May 14, 2015 | December 11, 2017 |
| NCT02488330 | Completed | Phase 3 | An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study | August 27, 2015 | June 29, 2018 |
| NCT02507375 | Completed | Phase 1 | A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | September 2006 | December 2008 |
| NCT02574078 | Completed | Phase 1/Phase 2 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) | November 23, 2015 | April 15, 2020 |
| NCT02595450 | Completed | A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer | September 2008 | November 2014 | |
| NCT02625168 | Completed | Phase 2 | Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC | January 2013 | December 2014 |
| NCT02694536 | Completed | Phase 3 | A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer | August 1, 2006 | November 19, 2009 |
| NCT02723578 | Completed | Phase 2 | Pemetrexed and Erlotinib for Metastatic Colorectal Cancer | December 1, 2015 | December 2018 |
| NCT02774278 | Completed | Phase 2 | A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC) | July 2005 | June 2009 |
| NCT02942095 | Completed | Phase 1 | Study of Ixazomib and Erlotinib in Solid Tumors | March 6, 2017 | December 7, 2022 |
| NCT02961374 | Completed | Phase 2 | Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer | October 27, 2017 | September 27, 2021 |
| NCT03076164 | Completed | Phase 1/Phase 2 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | March 1, 2017 | December 18, 2020 |
| NCT03653546 | Completed | Phase 2/Phase 3 | First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases | October 29, 2018 | July 12, 2022 |
| NCT05081674 | Completed | Phase 2 | Brazilian Lung Immunotherapy Study | January 1, 2020 | July 30, 2023 |
| NCT00452413 | Completed | Phase 1/Phase 2 | A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer | May 2007 | November 2013 |
| NCT00456833 | Completed | Phase 1 | Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy | June 2005 | |
| NCT00457392 | Completed | Phase 3 | A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone | July 2007 | December 2012 |
| NCT00461708 | Completed | Phase 2 | A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival | May 2007 | November 2010 |
| NCT00462995 | Completed | Phase 2 | Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT) | May 2006 | February 2012 |
| NCT00473083 | Completed | Phase 2 | Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer | January 2009 | August 2013 |
| NCT00476476 | Completed | Phase 2 | Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar | December 2006 | October 2012 |
| NCT00480584 | Completed | Phase 1 | A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | April 2007 | November 2012 |
| NCT00495872 | Completed | Phase 1 | Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor | June 2007 | |
| NCT00497224 | Completed | Phase 2 | Phase II Trial of Erlotinib in Advanced Pancreatic Cancer | November 2006 | June 2013 |
| NCT00518011 | Completed | Phase 2 | A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer. | August 2007 | February 2009 |
| NCT00520013 | Completed | Phase 2 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | August 2007 | November 2013 |
| NCT00531960 | Completed | Phase 2 | A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer. | January 2008 | January 2010 |
| NCT00536640 | Completed | Phase 2 | Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab | November 2007 | May 2012 |
| NCT00536861 | Completed | Phase 1 | Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer | May 2006 | December 2007 |
| NCT00543504 | Completed | Phase 1 | Bevacizumab in Multiple Phase I Combinations | October 10, 2007 | April 29, 2020 |
| NCT00543842 | Completed | Phase 1 | Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer | December 2007 | December 2013 |
| NCT00547105 | Completed | Phase 2 | Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | June 25, 2007 | July 6, 2017 |
| NCT00550173 | Completed | Phase 2 | A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer | November 2007 | January 2012 |
| NCT00553800 | Completed | Phase 2 | Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer | July 5, 2007 | June 1, 2011 |
| NCT00563784 | Completed | Phase 2 | TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | November 2007 | May 30, 2018 |
| NCT00567359 | Completed | Phase 2 | Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR | December 2007 | December 2017 |
| NCT00570232 | Completed | Phase 2 | UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer | December 2007 | March 2015 |
| NCT00574366 | Completed | Phase 1 | Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer | December 2005 | February 2009 |
| NCT00577707 | Completed | Phase 2 | Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON) | November 2007 | December 2011 |
| NCT00591123 | Completed | Phase 2 | Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia | December 2007 | September 2015 |
| NCT00596648 | Completed | Phase 1/Phase 2 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer | December 2007 | |
| NCT00602030 | Completed | Phase 1/Phase 2 | Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC | January 8, 2008 | February 1, 2012 |
| NCT00603915 | Completed | Phase 2 | A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer | June 2006 | April 2011 |
| NCT00606502 | Completed | Phase 2 | Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment | January 2008 | June 24, 2010 |
| NCT04455594 | Not yet recruiting | Phase 2 | Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC | October 2020 | October 2025 |
| NCT06161558 | Not yet recruiting | Phase 1 | Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors | June 23, 2024 | November 16, 2027 |
| NCT04981509 | Recruiting | Phase 2 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | June 10, 2022 | December 31, 2024 |
| NCT04341181 | Recruiting | Phase 2 | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling | August 24, 2020 | April 30, 2025 |
| NCT05904457 | Recruiting | Phase 2 | A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer | January 2, 2023 | January 31, 2026 |
| NCT02925234 | Recruiting | Phase 2 | The Drug Rediscovery Protocol (DRUP Trial) | August 2016 | December 2027 |
| NCT05827614 | Recruiting | Phase 1 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications | March 24, 2023 | September 30, 2027 |
| NCT01927744 | Recruiting | Phase 2 | Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection | December 16, 2013 | December 31, 2024 |
| NCT05525858 | Recruiting | KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II | September 28, 2022 | September 2025 | |
| NCT05834348 | Recruiting | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | June 26, 2023 | February 3, 2025 | |
| NCT02194738 | Recruiting | N/A | Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | September 26, 2014 | September 28, 2026 |
| NCT03297606 | Recruiting | Phase 2 | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | March 23, 2018 | January 31, 2027 |
| NCT04449874 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | July 29, 2020 | November 30, 2024 |
| NCT01320501 | Suspended | Phase 4 | Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer | October 2009 | August 2016 |
| NCT02991651 | Suspended | Phase 1 | Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC | May 2016 | December 31, 2024 |
| NCT01297101 | Temporarily not available | Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy | |||
| NCT00570258 | Terminated | Phase 2 | Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy | September 2006 | December 2017 |
| NCT01284335 | Terminated | Phase 1 | A Safety Study in Participants With Advanced Solid Tumors | July 2008 | May 2016 |
| NCT00448240 | Terminated | Phase 2/Phase 3 | Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer | February 2007 | January 2015 |
| NCT00452075 | Terminated | Phase 2 | Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy | March 2007 | August 2010 |
| NCT01182350 | Terminated | Phase 2 | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | September 2011 | June 2016 |
| NCT01189435 | Terminated | Phase 2 | Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib | August 2010 | January 2012 |
| NCT01205685 | Terminated | Phase 2 | Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer | May 2010 | July 2011 |
| NCT00522249 | Terminated | Phase 1/Phase 2 | Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | May 2007 | July 2008 |
| NCT00522938 | Terminated | Phase 1/Phase 2 | Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | December 2007 | April 2008 |
| NCT02080078 | Terminated | Phase 1 | A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline | September 2014 | April 30, 2019 |
| NCT00532441 | Terminated | Phase 2 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas | September 2007 | August 2010 |
| NCT00391586 | Terminated | Phase 2 | Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung | July 2006 | May 2012 |
| NCT00539617 | Terminated | Phase 2 | Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery | October 5, 2007 | May 12, 2011 |
| NCT02134015 | Terminated | Phase 3 | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung) | March 2014 | November 11, 2016 |
| NCT01244191 | Terminated | Phase 3 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | January 11, 2011 | December 15, 2012 |
| NCT01247922 | Terminated | Phase 2 | Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 | May 23, 2011 | September 13, 2012 |
| NCT00351039 | Terminated | Phase 1/Phase 2 | Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer | July 2006 | September 2008 |
| NCT00564720 | Terminated | Phase 2 | Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer | December 2006 | March 2011 |
| NCT00412217 | Terminated | Phase 3 | A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer | November 2006 | December 2009 |
| NCT00597597 | Terminated | Phase 2 | Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer | April 2007 | April 2011 |
| NCT00442507 | Terminated | Phase 2 | Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction | March 2007 | January 2009 |
| NCT02206763 | Terminated | Phase 1 | Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC) | October 16, 2014 | February 16, 2017 |
| NCT03460678 | Terminated | Phase 4 | Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients. | February 28, 2018 | November 14, 2018 |
| NCT00640978 | Terminated | Phase 2 | Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer | March 2008 | March 2010 |
| NCT00642746 | Terminated | Phase 2 | Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) | March 2008 | December 2011 |
| NCT02318368 | Terminated | Phase 2 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label | November 2014 | January 2017 |
| NCT00673049 | Terminated | Phase 3 | Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer | May 2008 | April 2012 |
| NCT01455389 | Terminated | Phase 1/Phase 2 | TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer | February 2014 | September 28, 2020 |
| NCT02342353 | Terminated | Phase 1 | Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) | May 18, 2015 | February 6, 2018 |
| NCT00276744 | Terminated | Phase 2 | Individualized Drug Treatment for Treating Patients With Pancreatic Cancer | October 2005 | April 2010 |
| NCT01487174 | Terminated | Phase 3 | KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy | December 14, 2011 | July 25, 2013 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT02468661 | Terminated | Phase 1 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | September 23, 2015 | December 5, 2018 |
| NCT04165031 | Terminated | Phase 1/Phase 2 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | November 28, 2019 | October 30, 2020 |
| NCT02495233 | Terminated | Phase 1/Phase 2 | A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | September 8, 2015 | September 28, 2016 |
| NCT00749567 | Terminated | Phase 2 | Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer | July 2008 | September 2010 |
| NCT00750555 | Terminated | Phase 2 | Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer | September 2008 | December 2009 |
| NCT00750698 | Terminated | Phase 2 | A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib | August 2008 | June 2010 |
| NCT02556593 | Terminated | Phase 2 | IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases | September 2015 | April 2019 |
| NCT00766636 | Terminated | Phase 2 | Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy | September 2008 | |
| NCT02588261 | Terminated | Phase 3 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations | February 11, 2016 | December 21, 2017 |
| NCT00336700 | Terminated | Phase 2 | A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer | June 2006 | November 2011 |
| NCT00791544 | Terminated | Phase 1/Phase 2 | Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | November 2008 | November 2009 |
| NCT00830245 | Terminated | Phase 2 | A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer | January 2009 | July 2011 |
| NCT00832637 | Terminated | Phase 2 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers | August 2007 | March 15, 2017 |
| NCT00251589 | Terminated | Phase 1/Phase 2 | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) | January 2006 | October 2007 |
| NCT00841035 | Terminated | Phase 2 | 7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients | February 2009 | July 2011 |
| NCT00843531 | Terminated | Phase 2 | RAD001 and Erlotinib in Patients With Neuroendocrine Tumors | June 25, 2009 | August 20, 2016 |
| NCT02714530 | Terminated | Phase 2 | Thoracal Radiotherapy and Tarceva | April 1, 2014 | December 30, 2020 |
| NCT00947167 | Terminated | Phase 2 | A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors | March 2009 | May 2010 |
| NCT00954512 | Terminated | Phase 1/Phase 2 | Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) | September 25, 2009 | June 7, 2011 |
| NCT01822496 | Terminated | Phase 2 | Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | November 4, 2013 | June 4, 2018 |
| NCT02770014 | Terminated | Phase 2 | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | June 2016 | June 19, 2019 |
| NCT00996502 | Terminated | Phase 1/Phase 2 | Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | July 2006 | March 2010 |
| NCT00392665 | Terminated | Phase 2 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | October 2006 | December 2013 |
| NCT02775006 | Terminated | Phase 3 | Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma | October 14, 2016 | April 2019 |
| NCT01003938 | Terminated | Phase 2 | Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer | August 2009 | December 2012 |
| NCT01009203 | Terminated | Phase 2 | Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma | December 2009 | December 2012 |
| NCT01962896 | Terminated | Phase 2 | A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors | January 8, 2014 | January 27, 2018 |
| NCT01026844 | Terminated | Phase 1 | Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC) | July 2007 | November 2012 |
| NCT01990261 | Terminated | A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment | May 2013 | September 2014 | |
| NCT01032070 | Terminated | Phase 2 | Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma | September 27, 2010 | November 26, 2012 |
| NCT01038856 | Terminated | Phase 2 | Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera | December 2009 | February 2014 |
| NCT01059305 | Terminated | Phase 2 | Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin | February 2011 | March 2016 |
| NCT01108458 | Terminated | Phase 2 | A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma | July 2010 | March 2011 |
| NCT01110876 | Terminated | Phase 1/Phase 2 | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | June 2011 | July 2014 |
| NCT01115803 | Terminated | Phase 1 | A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors | March 2010 | June 2011 |
| NCT00784667 | Unknown status | Phase 2 | Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib | October 2008 | February 2011 |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT02031601 | Unknown status | Phase 4 | Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer | January 2014 | December 2017 |
| NCT02140333 | Unknown status | Phase 3 | Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC | August 2013 | December 2018 |
| NCT00977470 | Unknown status | Phase 2 | Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations | October 2009 | June 2021 |
| NCT02759614 | Unknown status | Phase 3 | Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations | April 1, 2016 | June 1, 2019 |
| NCT03126799 | Unknown status | Phase 2 | A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+) | November 1, 2016 | July 20, 2023 |
| NCT01131429 | Unknown status | Phase 2 | A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations | June 2010 | June 2015 |
| NCT02066038 | Unknown status | Phase 2 | Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | January 2014 | March 2016 |
| NCT04575415 | Unknown status | Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study | October 7, 2020 | December 2023 | |
| NCT01608841 | Unknown status | Phase 2 | The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib | July 2005 | October 2015 |
| NCT02015728 | Unknown status | N/A | Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors | December 2013 | December 2017 |
| NCT02655536 | Unknown status | Phase 2 | Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial | August 1, 2017 | December 2019 |
| NCT00591383 | Unknown status | Phase 1 | Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors | January 2008 | June 2013 |
| NCT00568841 | Unknown status | Phase 2 | Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC) | October 2007 | December 2009 |
| NCT02001896 | Unknown status | Phase 3 | Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation | December 2013 | June 2015 |
| NCT00440167 | Unknown status | Phase 3 | Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine | June 2006 | December 2012 |
| NCT03239015 | Unknown status | Phase 2 | Efficacy and Safety of Precision Therapy in Refractory Tumor | January 1, 2017 | December 31, 2023 |
| NCT02233049 | Unknown status | Phase 2 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | October 2014 | October 2018 |
| NCT02239952 | Unknown status | N/A | HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) | November 2014 | November 2021 |
| NCT02036359 | Unknown status | Phase 2 | Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca | May 2012 | |
| NCT01407822 | Unknown status | Phase 2/Phase 3 | Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer | December 5, 2011 | December 2022 |
| NCT01410214 | Unknown status | Phase 2 | Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations | May 2011 | July 2017 |
| NCT00620269 | Unknown status | Phase 2 | Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III | February 2008 | March 2015 |
| NCT00637910 | Unknown status | Phase 3 | Tarceva Italian Lung Optimization tRial | November 2007 | February 2013 |
| NCT01683175 | Unknown status | Phase 2 | Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation | August 2012 | October 2020 |
| NCT02037997 | Unknown status | Phase 2 | Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC | December 2013 | December 2017 |
| NCT00663689 | Unknown status | Phase 2 | Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer | March 2008 | January 2012 |
| NCT01091376 | Unknown status | Phase 2 | Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) | January 2010 | March 2013 |
| NCT00678964 | Unknown status | Phase 2 | Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | June 2006 | |
| NCT01729481 | Unknown status | Phase 2 | Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer | July 2012 | December 2017 |
| NCT01470716 | Unknown status | Phase 2 | Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations | January 2012 | June 30, 2022 |
| NCT01752205 | Unknown status | Phase 3 | Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma | November 2012 | November 2014 |
| NCT01763385 | Unknown status | Phase 2 | Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases | November 2012 | May 2016 |
| NCT00339586 | Unknown status | Phase 2 | First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene | January 2006 | |
| NCT02146118 | Unknown status | Phase 2 | A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma | April 2014 | March 2016 |
| NCT03110484 | Unknown status | Phase 2 | Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study | July 9, 2021 | June 14, 2024 |
| NCT00908336 | Unknown status | Phase 2 | Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen | March 2009 | December 2010 |
| NCT01796288 | Unknown status | Phase 2 | The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment | October 2012 | October 2017 |
| NCT02737228 | Unknown status | Phase 1/Phase 2 | Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer | March 2016 | August 2019 |
| NCT02886195 | Unknown status | Phase 3 | EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC | July 2016 | July 2019 |
| NCT00570375 | Withdrawn | Phase 2 | The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome | November 2007 | April 2009 |
| NCT01006096 | Withdrawn | Phase 2 | Erlotinib for Treatment of Psoriasis | ||
| NCT02277457 | Withdrawn | Early Phase 1 | Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations | September 2015 | |
| NCT02034097 | Withdrawn | Phase 2 | A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer | April 2014 | December 2016 |
| NCT02044601 | Withdrawn | Phase 1/Phase 2 | Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT) | June 2014 | |
| NCT00728000 | Withdrawn | Phase 2 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | August 2008 | August 2010 |
| NCT01728181 | Withdrawn | Phase 1/Phase 2 | A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation | November 2013 | March 2016 |
| NCT02689336 | Withdrawn | Phase 2 | Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors | August 6, 2016 | May 31, 2020 |
| NCT02355431 | Withdrawn | Phase 2 | Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | December 2014 | September 2015 |
| NCT01432119 | Withdrawn | Phase 1 | Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib | December 2012 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Tarceva
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2004
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2007
- Target (Drug list of Screening Committee of Anticancer Drugs)
- EGFR
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 非小細胞肺がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- （EGFR/exon19del
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- L858R）
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 膵がん